Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02568267 · ClinicalTrials.gov registry record · Phase 2
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
A Phase 2 study of Breast Cancer and Non-Small Cell Lung Cancer, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 2
- Development phase
- 534
- Enrollment target
- 20
- Study locations
NCT02568267 is a Phase 2 study of Breast Cancer and Non-Small Cell Lung Cancer that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 534 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (81% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT02568267, a Phase 2 study of Breast Cancer and Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 534 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.
Conditions Studied
Interventions
- DRUG Entrectinib
Study Locations (20)
California
- City of Hope Cancer Center - Duarte
- City of Hope Duarte - Comprehensive Cancer Center, Investigational Drug Services - Duarte
- Scripps Clinic - La Jolla
- University of California San Diego Moores Cancer Center - La Jolla
- Southern California Kaiser Permanente - Los Angeles
- University of Southern California Medical Center - Los Angeles
- Univ Of California Irvine College Of Medicine - Orange
- UCSF Mount Zion Medical Ctr - San Francisco
- UCSF Mission Bay - San Francisco
- Sarcoma Oncology Center - Santa Monica
- Sarcoma Oncology Research Center LLC - Santa Monica
Florida
- Florida Cancer Specialists - Sarasota - Sarasota
- H. Lee Moffitt Cancer Center and Research Inst. - Tampa
- Moffitt Cancer Center - Tampa
Arizona
- Dignity Health St Joseph's Hospital and Medical Center - Phoenix
- Mayo Clinic - Phoenix
Colorado
- University of Colorado Cancer Center - Aurora
Connecticut
- Yale University - New Haven
District of Columbia
- Georgetown University Medical Center Lombardi Cancer Center - Washington D.C.
Georgia
- University Cancer & Blood Center, LLC - Athens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 534 participants |
| Start Date | 2015-11-19 |
| Est. Completion | 2026-05-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02568267
The ClinicalTrials.gov registry entry for NCT02568267 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 534 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (81% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Entrectinib is the first listed.
NCT02568267 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT02568267 about?
NCT02568267 is a clinical study titled "Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)". This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.
What is the current status of trial NCT02568267?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 534 participants. The study started on 2015-11-19. Estimated completion is 2026-05-14.
What conditions does trial NCT02568267 study?
This clinical trial studies the following conditions: Breast Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer, Ovarian Cancer, Pancreatic Cancer.
What interventions are being tested in trial NCT02568267?
The interventions under investigation include: Entrectinib (DRUG).
Who is sponsoring clinical trial NCT02568267?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02568267 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.